Full-Time

Clinical Research Associate

Cardiovascular/Vaccine/Infectious Disease

Updated on 8/21/2026

Deadline 8/29/26
Merck

Merck

10,001+ employees

Pharmaceutical company developing medicines and vaccines

Compensation Overview

$96.2k - $151.4k/yr

+ Annual bonus + Long-term incentive

No H1B Sponsorship

Naperville, IL, USA + 13 more

More locations: Peoria, IL, USA | Houston, TX, USA | California, USA | Florida, USA | Dallas, TX, USA | Chicago, IL, USA | Colorado, USA | Flagstaff, AZ, USA | Rahway, NJ, USA | New York, NY, USA | Phoenix, AZ, USA | Tucson, AZ, USA | Bloomington, IL, USA

Remote

Must reside in Illinois, Colorado, South Florida, New York, California, Houston, or Dallas; travel is approximately 65%-75% of working time.

Bachelor's, Associate's, Certification

Category
Biology & Biotech (1)
Required Skills
Microsoft Office
Data Analysis

Get referred to Merck

See people who can refer or advise you

Requirements
  • A current driver's license is required.
  • Fluency in local languages and English, both verbal and written, is required.
  • A good understanding and working knowledge of clinical research, clinical trial phases, current Good Clinical Practice/International Council for Harmonisation guidelines, and country clinical research laws and guidelines is required.
  • A good understanding of global, country, and regional clinical research guidelines and the ability to work within them is required.
  • Hands-on knowledge of Good Documentation Practices is required.
  • Proven site management skills, including management of site performance and patient recruitment, are required.
  • A high level of monitoring skill with independent professional judgment is required.
  • Good information technology skills, including Microsoft Office and clinical information technology applications on computers, tablets, and mobile devices, are required.
  • The ability to understand and analyze data and metrics and act appropriately is required.
  • The ability to manage complex issues and work in a solution-oriented manner is required.
  • The ability to perform root cause analysis and implement preventive and corrective actions is required.
  • Effective time management, organizational, interpersonal, conflict management, and problem-solving skills are required.
  • The ability to work independently across multiple protocols, sites, and therapy areas is required.
  • The ability to set priorities and handle multiple tasks simultaneously in a changing environment is required.
  • The ability to work effectively in a multicultural matrix environment and maintain culturally sensitive working relationships is required.
  • A commitment to customer focus and high quality and compliance standards is required.
  • An Associate's degree, certificate, or equivalent qualification in a scientific or healthcare discipline with at least five years of relevant healthcare experience, including at least two years of direct site-management or monitoring experience in a biotechnology, pharmaceutical, or contract research organization is required; alternatively, a Bachelor's degree or higher with at least two years of direct site-management or monitoring experience in a biotechnology, pharmaceutical, or contract research organization is required.
Responsibilities
  • Ensure performance and compliance for assigned protocols and sites in a country.
  • Ensure study conduct complies with International Council for Harmonisation/Good Clinical Practice, country regulations, company policies and procedures, quality standards, and adverse-event reporting requirements under the oversight of the Clinical Research Associate Manager.
  • Act as the primary site contact and site manager throughout all phases of a clinical research study, taking overall responsibility for allocated sites.
  • Develop and expand the clinical research territory by finding and developing new sites.
  • Participate in internal meetings and workstreams as a subject matter expert for monitoring processes and systems.
  • Develop strong site relationships and ensure continuity of those relationships throughout all phases of the trial.
  • Perform clinical study site management and monitoring activities in compliance with Good Clinical Practice, sponsor standard operating procedures, local laws and regulations, the protocol, the site monitoring plan, and associated documents.
  • Gain an in-depth understanding of the study protocol and related procedures.
  • Coordinate and manage tasks with other sponsor roles to achieve site readiness.
  • Participate in and provide input on site selection and validation activities.
  • Perform remote and on-site monitoring and oversight activities using various tools to ensure site data are complete, accurate, and unbiased and that subjects' rights, safety, and well-being are protected.
  • Conduct validation, initiation, monitoring, and close-out visits, and record clear, comprehensive, and accurate visit and non-visit contact reports in a timely manner.
  • Collect, review, and monitor required regulatory documentation for study start-up, study maintenance, and study close-out.
  • Communicate with investigators and site staff regarding protocol conduct, recruitment, retention, protocol deviations, regulatory documentation, site audits and inspections, and overall site performance.
  • Identify, assess, and resolve site performance, quality, or compliance problems and escalate them through the defined Clinical Research Associate escalation pathway as appropriate, in collaboration with the Clinical Research Associate Manager, Clinical Research Manager, Therapeutic Area Head, and Clinical Research Director.
  • Work with country operations, finance, regulatory affairs, pharmacovigilance, legal, regional operations, headquarters functional areas, vendors, institutional review boards/independent ethics committees, and regulatory authorities in support of assigned sites.
  • Manage and maintain information and documentation in the Clinical Trial Management System, electronic Trial Master File, and other systems according to applicable timelines.
  • Support or lead audit and inspection activities as needed.
  • Perform co-monitoring visits where appropriate.
  • Following the country strategy, contribute to identifying potential sites and work with them to develop strong clinical research capabilities.
  • Travel domestically and internationally approximately 65%-75% of working time, typically two to three days per week.

Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $16.6 billion; management raised full-year guidance to $66.3-$67.3 billion.
  • Keytruda QLEX generated $463 million in Q2 2026, cushioning future intravenous Keytruda erosion.
  • SCRI partnership broadens oncology trial access across 200 community sites, accelerating enrollment.

What critics are saying

  • Gardasil weakness triggered 150 North Carolina layoffs in February 2026 and continues pressuring vaccines.
  • The Terns deal created a $5.7 billion charge, crushing 2026 adjusted EPS to $2.66-$2.76.
  • Keytruda still dominates sales; a 2028-2029 patent cliff would hit Merck's core franchise.

What makes Merck unique

  • Keytruda family produced $8.4 billion in Q2 2026 across earlier- and metastatic cancers.
  • Merck stacked first-in-class perioperative bladder, kidney, and melanoma approvals during July-August 2026.
  • Animal Health adds durable diversification, with INNOVAX ND-IBD-ILT USDA approval August 13, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-20%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Aug 20th, 2026
Merck takes $3.8M stake in AI vaccine developer Evaxion after licensing bacterial candidate

Merck & Company disclosed holding 1,214,126 shares of AI immunology firm Evaxion A/S in a regulatory filing on 10 August. Evaxion shares rose 2% to $3.17 following the announcement. The position follows Merck's September 2025 decision to in-license EVX-B3, Evaxion's discovery-stage vaccine candidate targeting an undisclosed bacterial pathogen. Argus raised its price target on Merck from $130 to $145 on 11 August, citing regulatory approvals and pipeline depth. Merck reported Q2 2026 revenue of $16.6 billion, up 5% year-over-year, driven by $8.4 billion from KEYTRUDA. Evaxion reported zero revenue in Q1 2026 with a net loss of $3.6 million. Hedge fund holdings in Merck fell from 100 funds in Q4 2025 to 98 in Q1 2026.

Yahoo Finance
Aug 20th, 2026
Merck dips 0.5% after 12.6% surge on positive cancer-vaccine trial results

Merck shares dipped approximately 0.5% to $151.39 on Thursday following a 12.6% surge the previous day, reaching a record close. The pharmaceutical company's stock jumped after positive results from a Phase 3 trial testing a personalized melanoma vaccine developed with Moderna. The 1,137-patient study met its primary endpoints for recurrence-free survival and distant-metastasis-free survival. The trial compared Keytruda alone against Keytruda plus intismeran in patients with surgically removed high-risk melanoma, with no new safety concerns identified. Merck and Moderna are also testing the vaccine platform in lung, bladder, kidney, pancreatic and stomach cancers. Keytruda generated approximately $8.4 billion in second-quarter sales, representing roughly half of Merck's revenue. The stock now trades 26.28% above its estimated fair value of $119.88.

Yahoo Finance
Aug 20th, 2026
Merck surges 12.6% as personalised cancer vaccine beats standard melanoma treatment

Merck announced its personalised cancer vaccine combined with immunotherapy Keytruda significantly improved outcomes for melanoma patients in a Phase 3 trial. The 135-year-old drugmaker's stock jumped 12.6% on 19 August following the news. The trial tested intismeran autogene, developed with Moderna, alongside Keytruda in patients with surgically removed stage IIB through IV melanoma. Patients receiving the combination stayed cancer-free longer and experienced delayed cancer spread compared to those on Keytruda alone. The treatment uses mRNA technology tailored to each patient's tumour mutations, training the immune system to target up to 34 specific genetic changes. It marks the first time an individualised cancer vaccine has shown positive results in late-stage testing. Keytruda generated $8.4 billion in second-quarter sales, representing over 50% of Merck's quarterly revenue.

Yahoo Finance
Aug 20th, 2026
Merck melanoma vaccine trial beats expectations, but RBC downgrades stock over $30B Keytruda patent cliff

Merck's promising Phase 3 melanoma trial results drew mixed reactions from Wall Street. RBC Capital downgraded Merck to 'Sector Perform' from 'Outperform', calling the stock's $150 valuation "unprecedented" for a company facing major patent expiry in two years. Key patents covering Keytruda, Merck's best-selling cancer drug that generated over $30 billion in 2025 and represents nearly half of its revenue, begin expiring in 2028. RBC said further gains would require the pipeline to exceed already elevated expectations. However, BofA maintained its 'Buy' rating, raising its price target to $166, citing confidence that Merck can offset Keytruda's patent challenges. BMO Capital raised its target to $170, noting the trial could represent $5.6 billion in potential peak revenue. The trial tested Intismeran Autogene with Keytruda in melanoma patients, significantly extending time without recurrence.

Yahoo Finance
Aug 20th, 2026
Moderna stock rockets 177% as mRNA cancer vaccine trial succeeds, Musk calls technology 'tremendous promise

Elon Musk endorsed mRNA technology on Wednesday, describing it as having "tremendous promise" and likening disease treatment to a "software problem" through artificial RNA. His comments followed a major cancer vaccine breakthrough by Moderna and Merck. The companies announced positive Phase 3 results for an individualised mRNA cancer vaccine — the first successful late-stage trial of its kind. The treatment showed significant improvement in recurrence-free and metastasis-free survival in melanoma patients when combined with Merck's Keytruda. Musk was responding to scientist Eric Topol, who highlighted the trial's success alongside progress in personalised mRNA vaccines for pancreatic cancer, triple-negative breast cancer, and non-small cell lung cancer. Moderna shares surged 177%, whilst BioNTech gained 21.96% and Arcturus Therapeutics rose 25.21%. Musk has previously promoted AI and synthetic RNA as paths to transforming healthcare.